Private Advisory Group LLC Sells 663 Shares of Johnson & Johnson (JNJ)

Private Advisory Group LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 11.1% in the second quarter, HoldingsChannel reports. The institutional investor owned 5,323 shares of the company’s stock after selling 663 shares during the period. Private Advisory Group LLC’s holdings in Johnson & Johnson were worth $646,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in JNJ. Cigna Investments Inc. New increased its stake in Johnson & Johnson by 12.1% during the 1st quarter. Cigna Investments Inc. New now owns 121,558 shares of the company’s stock worth $15,578,000 after buying an additional 13,103 shares in the last quarter. BTC Capital Management Inc. increased its stake in Johnson & Johnson by 17.3% during the 1st quarter. BTC Capital Management Inc. now owns 71,141 shares of the company’s stock worth $9,109,000 after buying an additional 10,494 shares in the last quarter. Lee Financial Co increased its stake in Johnson & Johnson by 341.1% during the 1st quarter. Lee Financial Co now owns 2,223 shares of the company’s stock worth $285,000 after buying an additional 1,719 shares in the last quarter. Anchor Capital Advisors LLC increased its stake in Johnson & Johnson by 3.0% during the 1st quarter. Anchor Capital Advisors LLC now owns 203,281 shares of the company’s stock worth $26,050,000 after buying an additional 5,881 shares in the last quarter. Finally, Kayne Anderson Rudnick Investment Management LLC increased its stake in Johnson & Johnson by 3.0% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 22,272 shares of the company’s stock worth $2,854,000 after buying an additional 653 shares in the last quarter. Institutional investors own 66.51% of the company’s stock.

JNJ has been the subject of several research reports. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, November 27th. Credit Suisse Group boosted their price objective on Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 price objective on shares of Johnson & Johnson in a research note on Friday, September 14th. Citigroup boosted their price objective on Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research note on Monday, October 22nd. Finally, Raymond James boosted their price objective on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $143.47.

In other news, CAO Ronald A. Kapusta sold 8,441 shares of the business’s stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the transaction, the chief accounting officer now directly owns 17,284 shares in the company, valued at approximately $2,508,772.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the transaction, the chief accounting officer now owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 351,748 shares of company stock worth $51,092,647. Insiders own 0.22% of the company’s stock.

Shares of Johnson & Johnson stock opened at $146.21 on Tuesday. The company has a market cap of $394.12 billion, a PE ratio of 20.03, a P/E/G ratio of 2.30 and a beta of 0.59. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.75. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.90 EPS. As a group, analysts expect that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 2.46%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

TRADEMARK VIOLATION WARNING: “Private Advisory Group LLC Sells 663 Shares of Johnson & Johnson (JNJ)” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2018/12/04/private-advisory-group-llc-sells-663-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Technical Analysis of Stocks and What It Means

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit